Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 68INDUSTRY 12UNKNOWN 3OTHER_GOV 2NIH 2NETWORK 2INDIV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Immunotherapy 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Cisplatin 49Capecitabine 41apatinib 34Gemcitabine 33Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Surgical Procedures, Operative 17Nivolumab 17pembrolizumab 16Exercise 16Metformin 15camrelizumab 14S 1 (combination) 14Radiation 14Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11toripalimab 10Vinorelbine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Tegafur × Clear all
NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Immunotherapy

NCT01037998 2009-12-23

UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer

Taipei Veterans General Hospital, Taiwan

Phase 2 Completed
115 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡